BALKAN MEDICAL JOURNAL, vol.31, no.1, pp.43-49, 2014 (SCI-Expanded)
Background: Anti-vascular endothelial growth factor (Anti-VEGF) agents are a promising approach to increase the efficacy of treatment for treatment-resistant prostate cancer.